(Press-News.org) Laboratory experiments conducted by scientists at Virginia Commonwealth University Massey Cancer Center suggest that a novel combination of the drugs ibrutinib and bortezomib could potentially be an effective new therapy for several forms of blood cancer, including diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).
The study, published in the British Journal of Hematology, showed that the experimental drug combination killed cancer cells through a form of cell suicide known as apoptosis, but was relatively non-toxic to normal, healthy cells. Ibrutinib is a new agent that inhibits the B-cell receptor (BCR) signaling complex, which plays an important role in the survival of malignant B-cells. It has shown very promising initial results in the treatment of patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL), DLBCL and MCL. The synergistic interaction of the two drugs proved lethal even to lymphoma cells that had become resistant to bortezomib, when used alone.
"Bortezomib is currently used to treat MCL and multiple myeloma, but, unfortunately, many patients develop resistance to the drug," says the study's principle investigator Steven Grant, M.D., Shirley Carter Olsson and Sture Gordon Olsson Chair in Oncology Research, associate director for translational research, program co-leader of Developmental Therapeutics and Cancer Cell Signaling research member at VCU Massey Cancer Center. "We are hopeful that this combination therapy may circumvent such resistance and eventually help fill an urgent need for more effective therapies for patients with these uncommon blood disorders."
With cultured DLBCL and MCL cells in laboratory experiments spearheaded by Girija Dasmahapatra, Ph.D., lead author of the study's manuscript and instructor in the Department of Internal Medicine at VCU School of Medicine, the scientists found that ibrutinib blocked several molecular pathways that the cancer cells use for growth and survival. When ibrutinib was combined with bortezomib, the scientists observed a high level of synergism between the two drugs that resulted in profound cell death due to DNA damage, culminating in apoptosis. The research findings suggest that the effectiveness of the combination therapy against bortezomib-resistant lymphoma cells may stem from ibrutinib's ability to block signaling pathways used by the cancer cells to survive bortezomib exposure.
Specifically, exposure of DLBCL and MCL cells to ibrutinib blocked the cancer-promoting NF-κB, AKT and ERK1/2 signaling pathways. These signaling pathways provide cells with the ability to adapt to otherwise harmful environmental stimuli by transmitting messages from receptors located at the cell's surface to proteins within the cell that trigger a variety of biological processes. In particular, NF-κB, AKT and ERK1/2 have been shown to carry out many functions that allow cancer cells to survive and proliferate. Significantly, each of these pathways has been implicated in the development of resistance to proteasome inhibitors such as bortezomib.
"We have provided a framework for understanding how an agent like ibrutinib might be employed to enhance the activity of an established anti-cancer agent like bortezomib," says Grant. "We are currently working with representatives from the pharmaceutical industry and the National Cancer Institute to develop a new treatment strategy in which ibrutinib will be combined with proteasome inhibitors like bortezomib for the treatment of patients with lymphomas and potentially other blood cancers."
INFORMATION:
Grant and Dasmahapatra collaborated on this study with Hiral Patel and Tri Nguyen, Ph.D., from the Department of Internal Medicine at VCU School of Medicine; Paul Dent, Ph.D., Universal Corporation Distinguished Professor for Cancer Cell Signaling, vice chair of the department of neurosurgery and member of the Developmental Therapeutics research program at VCU Massey; and Richard I. Fisher, M.D., and Jonathan Friedberg, M.D., from the James T. Wilmot Cancer Center at the University of Rochester.
This research was supported by National Institutes of Health grants CA63753, CA93738 and CA100866; Lymphoma SPORE award 1P50 CA130805; award R6059-06 from the Leukemia and Lymphoma Society of America; the Multiple Myeloma Research Foundation; Myeloma Spore grant P50CA142509; the V Foundation; and, in part, by funding from VCU Massey Cancer Center's NIH-NCI Cancer Center Support Grant P30 CA016059.
The full manuscript of this study is available online at:
http://onlinelibrary.wiley.com/doi/10.1111/bjh.12206/abstract;jsessionid=D5165E95BC0631E5D3EAA2F6888ABC45.d01t02
News directors: Broadcast access to VCU Massey Cancer Center experts is available through VideoLink ReadyCam. ReadyCam transmits video and audio via fiber optics through a system that is routed to your newsroom. To schedule a live or taped interview, contact John Wallace, (804) 628-1550.
About VCU Massey Cancer Center:
VCU Massey Cancer Center is one of only 67 National Cancer Institute-designated institutions in the country that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It has one of the largest offerings of clinical trials in Virginia and serves patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 877-4-MASSEY for more information.
About VCU and the VCU Medical Center:
Virginia Commonwealth University is a major, urban public research university with national and international rankings in sponsored research. Located in downtown Richmond, VCU enrolls more than 31,000 students in 222 degree and certificate programs in the arts, sciences and humanities. Sixty-six of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 13 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
Experimental drug combination selectively destroys lymphoma cells
2013-02-06
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
2013-02-06
ROCHESTER, Minn. — Acute kidney injury strikes large numbers of hospitalized patients, including those with no prior kidney-related illness, and is one of the most costly and deadly conditions affecting critically ill patients. Findings published today in Critical Care from a Mayo Clinic-led, multicenter study identify two biomarkers of acute kidney injury that can be easily measured in urine and detect affected patients roughly 12 to 36 hours earlier than current tests.
"Failure to recognize and manage acute kidney injury in the early stages can lead to devastating ...
No clear evidence more gluten in new wheat is responsible for increase in celiac disease
2013-02-06
No clear evidence exists to support the idea that celiac disease is increasing in prevalence because farmers are growing strains of wheat that contain more gluten. That's the conclusion of an article in the ACS' Journal of Agricultural and Food Chemistry.
Donald D. Kasarda cites evidence that the incidence of celiac disease increased during the second half of the 20th century. Some estimates indicate that the disease is 4 times more common today. Also known as gluten intolerance, celiac disease occurs when gluten, a protein in wheat, barley and rye, damages the lining ...
Both heavy and incompatible drinking can increase the chances of divorce
2013-02-06
High levels of drinking have repeatedly been shown to predict divorce. The most cited explanation for this is that excessive alcohol use disrupts daily tasks and functioning, and increases spousal conflicts. A study of the effects of drinking among husbands versus wives, and of similar versus dissimilar drinking in couples, has found that both level of drinking and compatibility in drinking can have an influence on divorce.
Results will be published in the May 2013 issue of Alcoholism: Clinical & Experimental Research and are currently available at Early View.
"On ...
Childhood emotional abuse dramatically strong among male alcohol-dependent individuals
2013-02-06
Individuals who drink excessively or are alcohol dependent (AD) have reduced central serotonergic neurotransmission, which can have an impact on planning, judgment, self-control, and emotional regulation. Childhood maltreatment has also been found to have a negative impact on central serotonergic neurotransmission. A new evaluation of the impact of childhood maltreatment on central serotonergic dysfunction in AD individuals has found that self-reported childhood emotional abuse is associated with a 90-percent reduction in central serotonergic neurotransmission in male ...
Alcohol + diet drinks may increase intoxication more than alcohol + regular drinks
2013-02-06
An individual's breath alcohol concentration (BrAC) following alcohol intake is influenced by several factors, including food. While it is known that food delays the stomach emptying, thus reducing BrAC, only recently has the role of nonalcoholic drink mixers used with alcohol been explored as a factor influencing BrAC. A new comparison of BrACs of alcohol consumed with an artificial sweetener versus alcohol consumed with a sugared beverage has found that mixing alcohol with a diet soft drink can result in a higher BrAC.
Results will be published in the April 2013 ...
American Indians are at much greater risk of suicide following acute alcohol intoxication
2013-02-06
In 2009, according to the Centers for Disease Control and Prevention, suicide ranked as the 10th leading overall cause of death in the United States. Prior research has also shown that alcohol use disorders confer increased risk for suicide, and are second only to mood disorders as common among individuals who have committed suicide. A study of the prevalence and sociodemographic correlates of suicide involving acute alcohol intoxication among U.S. ethnic minorities has found that American Indians are at much greater risk than other groups.
Results will be published ...
MicroRNA molecule may serve as biomarker, target for brain metastases in breast cancer patients
2013-02-06
PHILADELPHIA — Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American Association for Cancer Research.
Currently, most deaths from breast cancer are a result of metastatic disease. New research shows that cancer stem-like cells — commonly defined as cells within a tumor with the capacity to initiate a new tumor, proliferate rapidly, differentiate and cause chemotherapy resistance — may play a role in ...
Hospice use rises; So does aggressive care
2013-02-06
PROVIDENCE, R.I. [Brown University] — A study published Feb. 6 in the Journal of the American Medical Association finds that while more seniors are dying with hospice care than a decade ago, they are increasingly doing so for very few days right after being in intensive care. The story told by the data, said the study's lead author, is that for many seniors palliative care happens only as an afterthought.
"For many patients, hospice is an 'add-on' to a very aggressive pattern of care during the last days of life," said Dr. Joan Teno, professor of health services policy ...
Lower proportion of Medicare patients dying in hospitals
2013-02-06
In a study that included data on more than 800,000 Medicare beneficiaries who died between 2000 – 2009, a lower proportion died in an acute care hospital in recent years, although both intensive care unit (ICU) use and the rate of health care transitions increased during the last month of life, according to a study appearing in the February 6 issue of JAMA.
"Site of death has been proposed as a quality measure for end-of-life care because, despite general population surveys indicating the majority of respondents and those with serious illness want to die at home, in ...
Use of ACE inhibitor by patients with peripheral artery disease may improve pain-free walking
2013-02-06
Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.
"Approximately 27 million individuals in Europe and North America have peripheral artery disease (PAD). Intermittent claudication occurs in approximately one-third ...